Despite the use of drugs such as renin–angiotensin–aldosterone (RAAS) inhibitors and sodium-glucose co-transporter-2 (SGLT-2) inhibitors to improve the symptoms and prognosis of DKD in recent years [30], DKD still accounts for half of the global burden of ESRD [31]. The gene discussed is SLC5A2; the disease is diabetic kidney disease.